- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
- SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
- Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
- Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
- Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
- Soligenix to Present at Upcoming Conferences
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
- Soligenix Announces Pricing of $4.75 Million Public Offering
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3856 |
---|---|
High | 0.388 |
Low | 0.341 |
Bid | 0.35 |
Offer | 0.3551 |
Previous close | 0.393 |
Average volume | 337.35k |
---|---|
Shares outstanding | 15.80m |
Free float | 15.79m |
P/E (TTM) | -- |
Market cap | 6.21m USD |
EPS (TTM) | -0.7395 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼